66 results
424B2
PLSE
Pulse Biosciences Inc
4 Jun 24
Prospectus for primary offering
4:05pm
of atrial fibrillation ("AF") and in a select few other markets where it could have a profound positive impact on healthcare for both patients
8-K
EX-99.1
PLSE
Pulse Biosciences Inc
4 Jun 24
Pulse Biosciences, Inc. Announces Commencement of Rights Offering
4:04pm
on healthcare for both patients and providers.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among
SD
EX-1.01
PLSE
Pulse Biosciences Inc
31 May 24
Conflict minerals disclosure
4:18pm
where it could have a profound positive impact on healthcare for both patients and providers.
Pulse Biosciences supports the goal of avoiding the use
POS AM
PLSE
Pulse Biosciences Inc
28 May 24
Prospectus update (post-effective amendment)
5:19pm
fibrillation ("AF") and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.
Our
8-K
EX-99.1
PLSE
Pulse Biosciences Inc
20 May 24
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
4:10pm
of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers
8-K
EX-99.1
j8nfstet d3dws4
15 May 24
Pulse Biosciences Enhances Executive Leadership Team
9:05am
8-K
EX-99.1
ufj0s
9 May 24
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
9:09am
8-K
EX-99.1
8kakkb gn
7 May 24
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
4:14pm
8-K
EX-99.1
8ib3ga
2 May 24
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
9:09am
8-K
EX-99.2
fv5k24fcy
28 Mar 24
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
4:18pm
8-K
EX-99.1
24mmw1wiwvjik zmu
28 Mar 24
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
4:18pm
8-K
EX-99.1
qvrln
11 Mar 24
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
9:10am
8-K
EX-99.1
po83h
14 Feb 24
Other Events
9:22am
8-K
EX-99.1
vzctyua4hr2 uju
2 Jan 24
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
9:20am
8-K
EX-99.1
a3o poenpuyimmh3a
20 Dec 23
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
9:06am
8-K
EX-99.1
lmaaqe 2m2
21 Nov 23
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
9:03am